In Vivo Accumulation of Regulatory T Cells Using Eliglustat-Loaded Cryogels.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40525671.
- Also identified by DOI 10.1002/adhm.202501529 and PMC identifier 12354322.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Regulatory T cells (T<sub>regs</sub>) maintain immune homeostasis and their adoptive transfer is being widely explored to mitigate inflammatory and autoimmune conditions. Here a biomaterial is developed to accumulate T<sub>regs</sub> at a specific anatomic location to bypass the need for ex vivo T<sub>reg</sub> isolation and adoptive transfer. It is first shown that eliglustat, an FDA-approved inhibitor of UDP-glucose ceramide glucosyltransferase, promotes T<sub>regs</sub> from both naïve and activated CD4<sup>+</sup> T cells in vitro. Click-crosslinked cryogels fabricated from alginate and collagen allow for a sustained release of CXCL10 or CXCL11, and when injected in subcutaneous tissues led to the enrichment of effector and memory T cells to the scaffolds. Loading eliglustat into these cryogels significantly enhances the local accumulation of T<sub>regs</sub> in vivo. These findings demonstrate that eliglustat-loaded cryogels offer a simple yet effective biomaterial strategy to boost T<sub>reg</sub> directly in vivo, potentially providing a targeted method to treat various inflammatory and autoimmune diseases.
Medical subject headings
- T-Lymphocytes, Regulatory
- Pyrrolidines
- Cryogels
- Biocompatible Materials